| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA012224 |
| P8608 | Fatcat ID | release_c4jlbjiiifhivoiagg4ajyf4ta |
| P698 | PubMed publication ID | 11832530 |
| P2093 | author name string | Ronald L Hamilton | |
| Ian F Pollack | |||
| Richard Sposto | |||
| James M Boyett | |||
| Allan J Yates | |||
| Jonathan L Finlay | |||
| Emiko J Holmes | |||
| Children's Cancer Group | |||
| Sydney D Finkelstein | |||
| Judith Burnham | |||
| Jeffrey Woods | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 420-427 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Expression of p53 and prognosis in children with malignant gliomas. | |
| P478 | volume | 346 |
| Q44626144 | A comparative immunohistochemistry of O6-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocytomas. |
| Q64227444 | A microRNA profile of pediatric glioblastoma: The role of NUCKS1 upregulation |
| Q54774848 | A novel microdissection and genotyping of follicular-derived thyroid tumors to predict aggressiveness |
| Q73404180 | A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression |
| Q36108450 | AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation |
| Q34132964 | Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas |
| Q30870633 | Advances in the management of paediatric high-grade glioma |
| Q33237311 | Advances in treatment of pediatric brain tumors |
| Q34196216 | Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group |
| Q46749960 | Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas |
| Q48485483 | Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors |
| Q36718046 | Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience |
| Q43422757 | Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas |
| Q37914391 | Ataxia resulting from posterior fossa tumors of childhood and other mass lesions |
| Q80510573 | Biology and therapy of malignant solid tumors in childhood |
| Q34203979 | Biology, genetics and imaging of glial cell tumours |
| Q37980395 | Brain tumors in children--current therapies and newer directions |
| Q48369347 | Characterization of glioblastomas in young adults |
| Q36908335 | Childhood brain tumors: accomplishments and ongoing challenges |
| Q33970971 | Childhood brain tumors: epidemiology, current management and future directions |
| Q38083799 | Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant Histone 3 Tail |
| Q34565424 | Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma |
| Q36048214 | Clinical and molecular characteristics of congenital glioblastoma |
| Q90448649 | Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children |
| Q55471414 | Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. |
| Q87202670 | Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database |
| Q33894483 | Comparison of survival between the UK and US after surgery for most common pediatric CNS tumors. |
| Q37861427 | Congenital Brain Tumors: Diagnostic Pitfalls and Therapeutic Interventions |
| Q45742366 | Congenital Glioblastoma Multiforme: Complete Resection with Long-Term Survival and a Novel Technique of Contralateral Cystoventriculostomy |
| Q48185223 | Congenital glioblastoma: a clinicopathologic and genetic analysis |
| Q92370079 | DIVERSet JAG Compounds Inhibit Topoisomerase II and Are Effective Against Adult and Pediatric High-Grade Gliomas |
| Q39870296 | DJ-1 expression in glioblastomas shows positive correlation with p53 expression and negative correlation with epidermal growth factor receptor amplification |
| Q35922426 | Dendritic cell-based immunotherapy of malignant gliomas |
| Q36908083 | Diagnostic and therapeutic stratification of childhood brain tumors: implications for translational research |
| Q34286305 | Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. |
| Q55463980 | Distinct molecular signatures in pediatric infratentorial glioblastomas defined by aCGH. |
| Q33772206 | Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene |
| Q52142503 | Expression and Prognostic Significance of p53 in Glioma Patients: A Meta-analysis |
| Q28483802 | Expression of TIP-1 Confers Radioresistance of Malignant Glioma Cells |
| Q40950711 | Genome-wide copy number analysis in pediatric glioblastoma multiforme |
| Q38022859 | High-Grade Gliomas in Children |
| Q37617838 | Histology and molecular pathology of pediatric brain tumors |
| Q34458930 | IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group |
| Q93173697 | Identification of KIF15 as a potential therapeutic target and prognostic factor for glioma |
| Q33884504 | Immunohistochemical Assessment of MGMT Expression and p53 Mutation in Glioblastoma Multiforme |
| Q35070545 | Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. |
| Q34666875 | Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo |
| Q37023302 | Initial management of childhood brain tumors: neurosurgical considerations |
| Q43231168 | Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol |
| Q36010103 | Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas |
| Q35925137 | Long-term follow-up of children treated for high-grade gliomas: children's oncology group L991 final study report. |
| Q48308652 | Long-term survival in children under 3 years of age with low-grade astrocytoma |
| Q35972863 | Long-term survival of children less than six years of age enrolled on the CCG-945 phase III trial for newly-diagnosed high-grade glioma: a report from the Children's Oncology Group |
| Q38544218 | Low-grade gliomas in children: single institutional experience in 198 cases. |
| Q43002702 | MGMT gene promoter methylation in pediatric glioblastomas. |
| Q46901432 | MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. |
| Q34002994 | Mesenchymal migration as a therapeutic target in glioblastoma |
| Q55472131 | Microdissection genotyping of gliomas: therapeutic and prognostic considerations. |
| Q34565801 | Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group |
| Q26785952 | Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment |
| Q35104265 | Molecular abnormalities and correlations with tumor response and outcome in glioma patients |
| Q35918862 | Molecular analysis of pediatric brain tumors |
| Q38070437 | Molecular diagnostics in paediatric glial tumours |
| Q55349951 | Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. |
| Q37208038 | Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas |
| Q37909392 | Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges |
| Q36695883 | Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage |
| Q55472005 | Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. |
| Q36453264 | New concepts in the treatment of brain tumors in very young children |
| Q39374292 | Novel Multiple Apoptotic Mechanism of Shikonin in Human Glioma Cells |
| Q35179617 | OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. |
| Q35218793 | Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945. |
| Q38013990 | Paediatric and adult malignant glioma: close relatives or distant cousins? |
| Q37564201 | Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy |
| Q38074094 | Paediatric spinal glioblastoma: case report and review of therapeutic strategies |
| Q36391419 | Past, present, and future strategies in the treatment of high-grade glioma in children |
| Q26801528 | Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma |
| Q48155429 | Pattern of recurrence in paediatric malignant glioma: an institutional experience |
| Q36902043 | Pediatric CNS tumors: current treatment and future directions. |
| Q38039443 | Pediatric High Grade Glioma: a Review and Update on Tumor Clinical Characteristics and Biology |
| Q55277238 | Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes. |
| Q37797364 | Pediatric brain tumors: a histologic and genetic update on commonly encountered entities |
| Q37533670 | Pediatric brain tumors: current treatment strategies and future therapeutic approaches |
| Q38233425 | Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism? |
| Q37284256 | Pediatric glioblastomas: a histopathological and molecular genetic study |
| Q39208269 | Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. |
| Q36273006 | Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches |
| Q37564835 | Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas |
| Q34364959 | Pediatric primary intramedullary spinal cord glioblastoma |
| Q51103541 | Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology |
| Q40837566 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study |
| Q41138860 | Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study |
| Q35996275 | Prognosis-related molecular markers in pediatric central nervous system tumors |
| Q38203283 | Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment |
| Q43154532 | Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas |
| Q34191508 | Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas |
| Q34514088 | Risk assignment in childhood brain tumors: the emerging role of molecular and biologic classification |
| Q47811682 | Screening critical genes associated with malignant glioma using bioinformatics analysis |
| Q40551019 | Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides |
| Q35799863 | Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma |
| Q48906956 | Significance of p53 and CD31 in astrogliomas |
| Q36929844 | Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma |
| Q48743328 | Syndromes predisposing to pediatric central nervous system tumors: lessons learned and new promises |
| Q88768084 | TP53 gain-of-function mutation promotes inflammation in glioblastoma |
| Q36800148 | Targeted therapy for BRAFV600E malignant astrocytoma. |
| Q48429498 | Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases |
| Q38075541 | The impact of the written request process on drug development in childhood cancer |
| Q37292382 | The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience |
| Q90111510 | The molecular oncology of bilateral high-grade thalamic astrocytomas in children |
| Q36308544 | The point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non HCC prevalent area in China |
| Q38326253 | The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis |
| Q43259828 | The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas |
| Q36273008 | The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective |
| Q37904503 | Treatment of high-grade glioma in children and adolescents |
| Q46809466 | Tyrosine kinase expression in pediatric high grade astrocytoma |
| Q36499230 | Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma |
| Q33719157 | YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas |
| Q54751602 | [The role of molecular genetics in childhood cancer] |
| Q33695954 | p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). |
Search more.